Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ping An Biomedical (PASW) Receivables (2024 - 2025)

Ping An Biomedical filings provide 2 years of Receivables readings, the most recent being $2.4 million for Q3 2025.

  • On a quarterly basis, Receivables fell 67.07% to $2.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.4 million, a 67.07% decrease, with the full-year FY2025 number at $2.3 million, down 67.31% from a year prior.
  • Receivables hit $2.4 million in Q3 2025 for Ping An Biomedical, down from $4.1 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $7.2 million in Q3 2024 to a low of -$1.8 million in Q1 2024.